Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 18/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911204 | 1.00 | ADRB3 (0.70) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL6914674 | 1.00 | ADRB3 (0.70) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7110843 | 0.99 | ADRB3 (0.69) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7107397 | 0.99 | ADRB3 (0.69) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7110498 | 0.99 | ADRB3 (0.69) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7638625 | 0.97 | ADRB3 (0.67) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| SCHEMBL7251839 | 0.94 | ADRB3 (0.72) | ADRB3ADRA1ADRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7252857 | 0.94 | ADRB3 (0.71) | ADRB3ADRA1AADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL7252861 | 0.94 | ADRB3 (0.71) | ADRB3ADRA1AADRB2ADRB1 | |
| SCHEMBL7250660 | 0.93 | ADRB3 (0.75) | ADRB3ADRA1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | claimed |
| EP-1219604-A1 | METHOD FOR IMPROVING THE SOLUBILITY OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-07-03 | — | — | EP | claimed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | claimed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | claimed |
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | KADOWAKI TAKASHI (JP) | 2004-12-02 | — | — | US | disclosed |
| US-6696573-B1 | SYNTHESIS OF SUCH AS 2-(N-(2-(9H-CARBAZOL-2-YLOXY)ETHYL))-AMINO-1-((3 -METHYLSULFONYLAMINO)PHENYL)ETHANOL WITH ENHANCED OPTICAL PURITY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2004-02-24 | — | — | US | disclosed |
| US-6696573-B1 | SYNTHESIS OF SUCH AS 2-(N-(2-(9H-CARBAZOL-2-YLOXY)ETHYL))-AMINO-1-((3 -METHYLSULFONYLAMINO)PHENYL)ETHANOL WITH ENHANCED OPTICAL PURITY | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-12-04 | — | — | US | disclosed |
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2003-12-04 | — | — | US | disclosed |
| EP-0882707-B1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | ASAHI CHEMICAL IND (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | SMITHKLINE BEECHAM P.L.C. | 2003-04-17 | — | — | US | disclosed |
| EP-1174425-A1 | NOVEL METHOD FOR MANUFACTURING TRICYCLIC AMINO ALCOHOL DERIVATIVES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1174426-A1 | METHOD FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES THROUGH AZIDES | Asahi Kasei Kabushiki Kaisha (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1128845-A1 | COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTDIABETIC AGENT | SMITHKLINE BEECHAM PLC (GB) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001017962-A1 | PROCESSES FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2001-03-15 | — | — | WO | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| WO-2000027434-A1 | COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTIDIABETIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | ADRB3 1/4885ADRA1A 21/4885DRD2 212/4885 |
| US-20030073644-A1 | Combinations comprising a beta-agonist and a further antidiabetic agent | ADRB1, ADRB2, ADRB3 | ADRB3 3/4885ADRA1A 7/4885DRD2 902/4885 |
| US-20030225289-A1 | Process for the preparation of tricyclic amino alcohol derivatives | ADH1A, ADH1C, OXER1 | ADRB3 323/4885ADRA1A 77/4885DRD2 745/4885 |
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | ADIPOR1, FABP4, ADIPOR2 | ADRB3 6/4885ADRA1A 54/4885DRD2 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.